A comprehensive perioperative and stoma care reference for nurses practising in GCC healthcare settings, aligned with DHA and SCFHS competency frameworks.
Third most common cancer globally; increasing incidence in GCC linked to dietary westernisation, obesity, and sedentary lifestyle. Mean age at presentation in GCC is ~55 years — younger than Western cohorts.
Herniation of mucosa through muscular wall. Most common in sigmoid colon. Low-fibre diets prevalent in GCC populations increase risk.
Colorectal cancer is among the top 3 cancers in UAE, Saudi Arabia, Kuwait, and Qatar. Key regional drivers:
| Stage | TNM | Dukes | Description | 5-Year Survival |
|---|---|---|---|---|
| I | T1-2 N0 M0 | A | Tumour within bowel wall; no nodal spread | ~90% |
| II | T3-4 N0 M0 | B | Through bowel wall; no lymph nodes | ~75% |
| III | Any T N1-2 M0 | C | Lymph node involvement; no distant mets | ~50% |
| IV | Any T Any N M1 | D | Distant metastases (liver, lung, peritoneum) | ~15% |
CT staging (chest/abdomen/pelvis) + MRI rectum for rectal cancers. CEA baseline for surveillance.
History & Risk Stratification
Investigations
Historically standard; evidence now supports selective use. MBP alone is NOT recommended; combination with oral antibiotics (OABP) is preferred for colonic surgery.
Reduces surgical site infection (SSI) by targeting intraluminal flora. Combined MBP + OABP shows best outcomes in colorectal trials (SWAMP trial, MOBILE trial).
Enterostomal therapy (ET) nurse should site and mark the stoma before surgery. Optimal siting reduces complications by up to 70%.
Principles of Stoma Siting:
Site by Procedure:
Oral supplements enriched with arginine, omega-3, ribonucleotides. Reduces SSI and length of stay in colorectal cancer patients.
| Factor | Laparoscopic | Open |
|---|---|---|
| Incision | 3–5 small ports (5–12 mm) + specimen extraction | Midline laparotomy (15–25 cm) |
| Hospital stay | 2–4 days (ERAS) | 4–7 days |
| Return to activity | 2–4 weeks | 6–8 weeks |
| Pain | Less; less opioid requirement | More; epidural often used |
| Oncological outcome | Equivalent (CLASSIC, COLOR trials) | Standard |
| Conversion risk | 5–15% to open | N/A |
| Robotic option | Available at GCC tertiary centres | N/A |
| Procedure | Indication | Anastomosis | Stoma | Notes |
|---|---|---|---|---|
| Right Hemicolectomy | Caecal / ascending / hepatic flexure cancer | Ileocolic (side-to-side or end-to-end) | Usually none; ileostomy if high risk | Laparoscopic preferred; resect terminal ileum |
| Left Hemicolectomy | Descending colon / splenic flexure cancer | Colorectal or colocolic | Rarely; Hartmann's if perforated | IMA ligation; splenic flexure mobilisation |
| Anterior Resection (AR) | Upper/mid rectal cancer (>6 cm from AV) | Colorectal (stapled) | Loop ileostomy (protective, temporary) | TME technique; preserve autonomic nerves |
| Low Anterior Resection (LAR) | Lower rectal cancer (5–6 cm from AV) | Coloanal (hand-sewn or stapled) | Loop ileostomy mandatory | LARS syndrome post-op; longer recovery |
| Hartmann's Procedure | Emergency: perforated diverticulitis, obstructed cancer | None (oversewn rectal stump) | End colostomy (LIF) | Reversal possible 3–6 months later |
| APR (Abdominoperineal Resection) | Very low rectal / anal canal cancer (<4 cm AV) | None (permanent) | Permanent end colostomy (LIF) | Perineal wound; combined abdominal & perineal incisions |
| Subtotal/Total Colectomy | UC, FAP, emergency obstruction/volvulus | Ileorectal or IPAA | Ileostomy (temporary or permanent) | Multiple stages may be required |
ERAS Post-op Milestones:
Management:
| Complication | Definition / Signs | Timing | Management |
|---|---|---|---|
| Retraction | Stoma retracts below skin level; concave appearance; leakage risk | Early or late | Convex baseplate; barrier rings; ET nurse review; surgical revision if severe |
| Prolapse | Stoma protrudes >6 cm; oedematous; can be reducible or fixed | Weeks–months | Manual reduction (lubrication, cool compression); surgical revision if incarcerated/necrotic |
| Stenosis | Narrowing of stoma opening; ribbon stool; obstruction symptoms | Months–years | Digital dilation; surgical revision (revision often needed) |
| Parastomal hernia | Bowel protrusion through abdominal wall around stoma; bulge around stoma | Months–years (up to 50% of colostomies) | Support belt; surgical repair (mesh); resiting of stoma |
| Skin excoriation | Peristomal skin breakdown from effluent contact (especially ileostomy enzymes) | Any time | Better fit; barrier products; stoma powder; antifungal if candida present |
| Necrosis | Black/dusky colour; loss of viability | First 24–72 hrs | Immediate surgical review; torchlight assessment; may need revision |
Cluster of bowel dysfunction symptoms occurring after low anterior resection. Affects 60–80% of patients to varying degrees. Can significantly impair quality of life and return to work.
Symptoms:
Assessment & Management:
Select all applicable risk factors to calculate the patient's anastomotic leak risk category and guide post-operative monitoring intensity.
| Finding / Risk | Next Colonoscopy | Notes |
|---|---|---|
| Normal (average risk, age 45+) | 10 years | Or FIT annually |
| 1–2 small tubular adenomas (<10 mm) | 5 years | Low-risk adenomas |
| 3–4 adenomas OR any >10 mm OR villous/HGD | 3 years | High-risk adenomas |
| 5+ adenomas | 1 year | Consider genetic referral |
| Post-curative resection CRC (colonic) | 1 year then 3 years then 5 years | CEA monitoring concurrent |
| Post-curative resection rectal cancer | 3–6 months (rigid sigmoidoscopy/MRI) then annual | Local recurrence surveillance |
| First-degree relative CRC <50 years | Begin at 40 years or 10 years before relative's age | Earlier start |
| IBD (pancolitis) — 8–10 yrs duration | Annual chromoendoscopy | Dysplasia surveillance |
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) — Lynch syndrome. Autosomal dominant; MLH1, MSH2, MSH6, PMS2 gene mutations. Accounts for ~3% of CRC but proportionally higher in younger GCC patients.
Amsterdam II Criteria (refer if 3 or more):
APC gene mutation; autosomal dominant. Hundreds to thousands of colonic polyps from adolescence. Near 100% lifetime CRC risk if untreated.
Encourage:
Limit / Avoid (especially post-stoma formation):
DHA (Dubai Health Authority):
SCFHS (Saudi Commission):
Practical Nursing Advice: